These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 17329029)

  • 21. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.
    Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy.
    Lam JS; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6304S-9S. PubMed ID: 15448022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma.
    Smaldone MC; Fung C; Uzzo RG; Haas NB
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):765-91. PubMed ID: 21763967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting.
    Bregni M; Bernardi M; Servida P; Pescarollo A; Crocchiolo R; Treppiedi E; Corradini P; Ciceri F; Peccatori J
    Bone Marrow Transplant; 2009 Aug; 44(4):237-42. PubMed ID: 19234510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
    Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
    Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular markers for predicting prognosis of renal cell carcinoma.
    Nogueira M; Kim HL
    Urol Oncol; 2008; 26(2):113-24. PubMed ID: 18312928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy and gene therapy.
    Gitlitz BJ; Belldegrun A; Figlin RA
    Semin Urol Oncol; 1996 Nov; 14(4):237-43. PubMed ID: 8946624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric renal cell carcinoma.
    Sausville JE; Hernandez DJ; Argani P; Gearhart JP
    J Pediatr Urol; 2009 Aug; 5(4):308-14. PubMed ID: 19443274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
    Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
    J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Research advances in Xp11.2 translocation renal cell carcinoma].
    Huang JH; Zhou FJ
    Ai Zheng; 2008 Sep; 27(9):1006-8. PubMed ID: 18799045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Aberrant methylation of tumor suppressor genes in renal cell carcinoma].
    Zhang Q; Jin J; Tao Q
    Ai Zheng; 2007 Nov; 26(11):1276-80. PubMed ID: 17991333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
    Wood CG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers in clear cell renal cell carcinoma.
    George S; Bukowski RM
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1737-47. PubMed ID: 18062748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New treatment approaches in renal cell carcinoma.
    Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
    Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.